This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.
Subjects aged 19 years or older at the time of screening.
Subjects with a body weight greater than 50 kg (≥45 kg for females) and a body mass index (BMI) between 18.0 and 30.0 kg/m² at screening.
Subjects with no clinically significant congenital or chronic diseases, pathological symptoms or findings at screening.
Subjects determined by the principal investigator to be suitable for diagnostic procedures and electrocardiogram assessments
Subjects with clinically significant diseases or a history of conditions involving the digestive, cardiovascular, endocrine, respiratory, hematologic/oncologic infectious, renal/genitourinary, psychiatric/neurologic, musculoskeletal, immune, otorhinolaryngologic, dermatologic, or ophthalmologic systems.
Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) or gastrointestinal disease that may affect drug absorption.
Subjects who have taken drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose, or drugs that may interfere with this clinical trial within 10 days before the first dose
Subjects who have participated in another clinical trial or bioequivalence study and received an investigational drug within 6 months before the first administration.
Crossover
treatment A
DrugUIC202502 1 Tab/day for 7 days
treatment B
DrugUIC202505 1 Tab/day for 7 days
treatment C
DrugUIC202502+UIC202505 2 Tab/day for 7 days
AUCτ
Evaluation PK
Cmax,ss
Evaluation PK
Click on the lead sponsor to view all of their trials.
